Interesting Article on Biotech valuationsI was doing a bit of digging on how to properly value Biotechs since I have always thought the model of "The market for *insert ailment* is X and if we capture only 5% of this market our market cap is _____" this has always seemed overly simple to me.
the article gives some interesting insights to a proper valuation, what do you think about this Bencro? Vestor? Eoganacht?
https://www.nature.com/bioent/2003/030101/full/nbt0901-813.html